Radiotherapy versus surgery within multimodality protocols for esophageal cancer - A meta-analysis of the randomized trials

Cancer Treatment Reviews

Volumn 38, Issue 6, 2012, Pages 599-604

  Pöttgen, Christoph ^a   Stuschke, Martin ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Chemoradiotherapy; Meta analysis; Resectable

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; PACLITAXEL;

CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMORBIDITY; CONTINUOUS INFUSION; DISTANT METASTASIS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; HUMAN; META ANALYSIS; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RADIATION DOSE FRACTIONATION; REVIEW; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT OUTCOME;

CAUSE OF DEATH; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84861670078     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.10.005     Document Type: Review

References (47)

1. Siewert J.R., Stein H.J., Feith M., Bruecher B.L., Bartels H., Fink U. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg 2001, 234:360-367.
2. Rice T.W., Rusch V.W., Apperson-Hansen C., et al. Worldwide esophageal cancer collaboration. Dis Esophagus 2009, 22:1-8.
3. Ando N., Ozawa S., Kitagawa Y., Shinozawa Y., Kitajima M. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg 2000, 232:225-232.
4. Law S., Kwong D.L., Kwok K.F., et al. Improvement in treatment results and long-term survival of patients with esophageal cancer: impact of chemoradiation and change in treatment strategy. Ann Surg 2003, 238:339-347.
5. Law S., Wong K.H., Kwok K.F., Chu K.M., Wong J. Predictive factors for postoperative pulmonary complications and mortality after esophagectomy for cancer. Ann Surg 2004, 240:791-800.
6. Hofstetter W., Swisher S.G., Correa A.M., et al. Treatment outcomes of resected esophageal cancer. Ann Surg 2002, 236:376-384.
7. Lv J., Cao X.F., Zhu B., Ji L., Tao L., Wang D.D. Effect of neoadjuvant chemoradiotherapy on prognosis and surgery for esophageal carcinoma. World J Gastroenterol 2009, 15:4962-4968.
8. Gebski V., Burmeister B., Smithers B.M., Foo K., Zalcberg J., Simes J. Australasian Gastro-Intestinal Trials Group. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007, 8:226-234.
9. D'Amico T.A. Outcomes after surgery for esophageal cancer. Gastrointest Cancer Res 2007, 1:188-196.
10. Pennathur A., Luketich J.D. Resection for esophageal cancer: strategies for optimal management. Ann Thorac Surg 2008, 85. S751-6.
11. Steyerberg E.W., Neville B.A., Koppert L.B., et al. Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score. J Clin Oncol 2006, 24:4277-4284.
12. Bosset J.F., Gignoux M., Triboulet J.P., et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997, 337:161-167.
13. Urba S.G., Orringer M.B., Turrisi A., Iannettoni M., Forastiere A., Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001, 19:305-313.
14. Tepper J., Krasna M.J., Niedzwiecki D., et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008, 26:1086-1092.
15. Lee J.L., Parl S.I., Kim S.B., et al. A single institutional phase III trial of preoperative chemotherapy with hyperfractionated radiotherapy with surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol 2004, 15:947-954.
16. Le Prise E., Etienne P.L., Meunier B., et al. A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 1994, 73:1179-1184.
17. Wong R., Malthaner R. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev 2006, 1:CD002092.
18. Earlam R. An MRC prospective randomised trial of radiotherapy versus surgery for operable squamous cell carcinoma of the oesophagus. Ann R Coll Surg Engl 1991, 73:8-12.
19. Stahl M., Stuschke M., Lehmann N., et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005, 23:2310-2317.
20. Bedenne L., Michel P., Bouché O., et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007, 25:1160-1168.
21. Parmer M., Torri V., Stewart I. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998, 17:2815-2834.
22. Moodie P.F., Nelson N.A., Koch G.G. A non-parametric procedure for evaluating treatment effect in the meta-analysis of survival data. Stat Med 2004, 23:1075-1093.
23. Ho K.F., Fowler J.F., Sykes A.J., Yap B.K., Lee L.W., Slevin N.J. IMRT dose fractionation for head and neck cancer: variation in current approaches will make standardisation difficult. Acta Oncol 2009, 48:431-439.
24. Higgins J.P.T., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
25. Gleser L.J., Olkin I. Models for estimating the number of unpublished studies. Stat Med 1996, 15:2493-2507.
26. last assessed June 2011. http://www.sign.ac.uk/guidelines/fulltext/50/checklist2.html.
27. Gray J.R., Hainsworth J.D., Meluch A.A., et al. Concurrent paclitaxel/carboplatin/infusional 5-FU/radiation therapy (RT) with or without subsequent esophageal resection in patients with localized esophageal cancer: a Minnie Pearl Cancer Research Network trial. J Clin Oncol 2005, 23(16S):4018. abstract.
28. Stahl M., Wilke H., Lehmann N., Stuschke M. German Oesophageal Cancer Study Group, long-term results of a phase III study investigating chemoradiation with and without surgery in locally advanced squamous cell carcinoma (LA-SCC) of the esophagus. J Clin Oncol 2008, 26(20S):4530. abstract.
29. Chiu P.W.Y., Chan A.C.W., Leung S.F., et al. Multicenter prospective randomized trial comparing standard esophagectomy with chemoradiotherapy for treatment of squamous esophageal cancer: early results from the Chinese University Research Group for Esophageal Cancer (CURE). J Gastrointest Surg 2005, 9:794-802.
30. Sun X., Yu J., Fan X., Ren R.M., Li M.H., Zhang G.L. Randomized clinical study of surgery versus radiotherapy alone in the treatment of resectable esophageal cancer in the chest. Chin J Oncol 2006, 28:784-787.
31. Yu J., Ren R., Sun X., et al. A randomized clinical study of surgery versus radiotherapy in the treatment of resectable esophageal cancer. J Clin Oncol 2006, 24(18S):4013. abstract.
32. Carstens H., Albertsson M., Friesland S., et al. A randomized trial of chemoradiotherapy versus surgery alone in patients with resectable esophageal cancer. J Clin Oncol 2007, 25(18S):4530. abstract.
33. Zhang Y.W., Chen L., Bai Y., Zheng X. Long-term outcomes of late course accelerated hyper-fractionated radiotherapy for localized esophageal carcinoma in Mainland China: a meta-analysis. Dis Esophagus 2011, 10.1111/j.1442-2050.2010.01173.x, [Epub ahead of print].
34. Stein H.J., Siewert J.R. Improved prognosis of resected esophageal cancer. World J Surg 2004, 28:520-525.
35. Bartels H., Stein H.J., Siewert J.R. Preoperative risk analysis and postoperative mortality of oesophagectomy for resectable oesophageal cancer. Br J Surg 1998, 85:840-844.
36. Stein H.J., Brücher B.L., Sendler A., Siewert J.R. Esophageal cancer: patient evaluation and pre-treatment staging. Surg Oncol 2001, 10:103-111.
37. Albain K.S., Swann R.S., Rusch V.W., et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009, 374:379-386.
38. van Meerbeeck J.P., Kramer G.W., Van Schil P.E., et al. European Organisation for Research and Treatment of Cancer-Lung Cancer Group. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 2007, 99:442-450.
39. Mariette C., Piessen G., Triboulet J.P. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol 2007, 8:545-553.
40. Mariette C., Triboulet J.P. Should resectable esophageal cancer be resected. Ann Surg Oncol 2006, 13:447-449.
41. Piessen G., Briez N., Triboulet J.P., Mariette C. Patients with locally advanced esophageal carcinoma nonresponder to radiochemotherapy: who will benefit from surgery?. Ann Surg Oncol 2007, 14:2036-2044.
42. Miyata H., Yamasaki M., Takiguchi S., et al. Salvage esophagectomy after definitive chemoradiotherapy for thoracic esophageal cancer. J Surg Oncol 2009, 100:442-446.
43. Tachimori Y., Kanamori N., Uemura N., Hokamura N., Igaki H., Kato H. Salvage esophagectomy after high-dose chemoradiotherapy for esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg 2009, 137:49-54.
44. D'Journo X.B., Michelet P., Dahan L., et al. Indications and outcome of salvage surgery for oesophageal cancer. Eur J Cardiothorac Surg 2008, 33:1117-1123.
45. Geh J.I., Bond S.J., Bentzen S.M., Glynne-Jones R. Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response. Radiother Oncol 2006, 78:236-244.
46. Welsh J., Palmer M.B., Ajani J.A., et al. Esophageal cancer dose escalation using a simultaneous integrated boost technique. Int J Radiat Oncol Biol Phys 2010, Nov 29. [Epub ahead of print].
47. Welsh J., Gomez D., Palmer M.B., et al. Intensity-Modulated Proton Therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study. Int J Radiat Oncol Biol Phys 2011, Apr 4. [Epub ahead of print].